Avalo Therapeutics, Inc. Stock Deutsche Boerse AG
Equities
C6K0
US05338F3064
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.9 EUR | 0.00% | -7.04% | +0.61% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.56M 9.78M |
---|---|---|---|---|---|
Net income 2024 * | -33M -30.56M | Net income 2025 * | -36M -33.33M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-11.2
x | P/E ratio 2025 * |
-10.5
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 week | -7.04% | ||
Current month | -7.04% | ||
1 month | -20.16% | ||
3 months | +101.22% | ||
6 months | -15.82% | ||
Current year | +0.61% |
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director of Finance/CFO | 40 | 17-12-31 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 21-11-09 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 20-10-11 |
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 9.9 | 0.00% | 0 |
24-06-06 | 9.9 | -0.20% | 0 |
24-06-05 | 9.92 | +0.61% | 0 |
24-06-04 | 9.86 | -6.98% | 0 |
24-06-03 | 10.6 | -0.47% | 0 |
Delayed Quote Deutsche Boerse AG, June 07, 2024 at 03:06 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- AVTX Stock
- C6K0 Stock